Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 1/20 | 0.40 |
| ▸ | ADH1C | P00326 | 1/20 | 0.40 |
| ▸ | ADH1A | P07327 | 1/20 | 0.40 |
| ▸ | ADH4 | P08319 | 1/20 | 0.40 |
| ▸ | ADH7 | P40394 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 5/20 | 0.35 |
| ▸ | METAP1 | P53582 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27705383 | 1.00 | ADH1B (0.40) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL5543967 | 1.00 | ADH1B (0.40) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL1666337 | 0.98 | ADH1B (0.37) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL1451000 | 0.93 | — | — | |
| SCHEMBL17102571 | 0.92 | ADH1B (0.35) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL456220 | 0.88 | — | — | |
| SCHEMBL3258085 | 0.87 | CYP1A2 (0.45) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL5543638 | 0.87 | CYP1A2 (0.45) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL5541873 | 0.87 | CYP1A2 (0.45) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL3031792 | 0.85 | EPHX1 (0.47) | CYP1A2EPHX1SIGMAR1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1009 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103936892-A | Solid catalyst component for olefin polymerization and catalyst | BEIJIG LIHE ZHIXIN TECHNOLOGY LTD | 2014-07-23 | — | — | CN | claimed |
| CN-103936893-A | Catalyst component for olefin polymerization and catalyst | BEIJIG LIHE ZHIXIN TECHNOLOGY LTD | 2014-07-23 | — | — | CN | claimed |
| CN-103922928-A | Ring substituted ether acid ester compound suitable for preparing olefin polymerization catalyst | BEIJING LIHE ZHIXIN TECHNOLOGY CO LTD | 2014-07-16 | — | — | CN | claimed |
| CN-103923238-A | Catalyst component for olefin polymerization and catalyst | BEIJING LIHE ZHIXIN TECHNOLOGY CO LTD | 2014-07-16 | — | — | CN | claimed |
| CN-103923237-A | Catalyst component for olefin polymerization and application thereof | BEIJING LIHE ZHIXIN TECHNOLOGY CO LTD | 2014-07-16 | — | — | CN | claimed |
| CN-102749401-B | Inspection method of traditional Chinese medicine composition twenty-five-ingredient lung disease preparation | SHANDONG ARURA PHARMACEUTICAL RES & DEV CO LTD | 2013-12-18 | — | — | CN | claimed |
| EP-3365334-B1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2024-07-17 | — | — | EP | disclosed |
| US-20240197679-A1 | NOVEL SHORT-ACTING PSYCHOACTIVE COMPOUNDS OF THE MDMA CLASS | Altrartis Therapeutics Inc. | 2024-06-20 | — | — | US | disclosed |
| US-20240199607-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2024-06-20 | — | — | US | disclosed |
| US-20240199543-A1 | Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same | MYDECINE INNOVATIONS GROUP INC. | 2024-06-20 | — | — | US | disclosed |
| EP-4384226-A2 | DIPHOSPHINE COMPOUNDS AND COMPLEXES | Cancer Research Technology Limited (GB) | 2024-06-19 | — | — | EP | disclosed |
| US-20240158443-A1 | Compositions And Methods of Synthesizing Shape Shifting Cyclic Peptides (Sscp) And Their Use in The Identification of Novel Therapeutic Compounds | UNIV COLORADO REGENTS (US) | 2024-05-16 | — | — | US | disclosed |
| EP-4364739-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING KIDNEY INJURY, AND AUTOPHAGY ACTIVATOR | OSAKA UNIVERSITY (JP) | 2024-05-08 | — | — | EP | disclosed |
| US-4443598-A | ANTIBIOTICS AND INTERMEDIATES | SHIONOGI & CO., LTD. (JP) | 1984-04-17 | — | — | US | disclosed |
| US-4439425-A | IMMUNOLOGY | CIBA-GEIGY CORPORATION (US) | 1984-03-27 | — | — | US | disclosed |
| EP-0005859-B1 | PROCESS FOR REDUCING METAL ION CONTENT OF AQUEOUS SOLUTIONS | DE NORA PERMELEC S.P.A. (IT) | 1983-02-16 | — | — | EP | disclosed |
| US-4366316-A | FROM OXAZOLINOAZETIDINONE AND ACID | SHIONOGI & CO., LTD. (JP) | 1982-12-28 | — | — | US | disclosed |
| US-4215009-A | COMPLEXING | ORONZIO DENORA IMPIANTI ELETTROCHIMICI S.P.A. (IT) | 1980-07-29 | — | — | US | disclosed |
| EP-0005859-A1 | Process for reducing metal ion content of aqueous solutions | DE NORA PERMELEC S.P.A. (IT) | 1979-12-12 | — | — | EP | disclosed |
| US-3980687-A | Intermediates for the preparation of 17-substituted-Δ4 -gonenes | ROUSSEL-UCLAF (FR) | 1976-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240197679-A1 | NOVEL SHORT-ACTING PSYCHOACTIVE COMPOUNDS OF THE MDMA CLASS | PNMT, HTR2C, SLC18A2 | ADH1B 3447/4885ADH1C 1375/4885ADH1A 834/4885 |
| US-20240158443-A1 | Compositions And Methods of Synthesizing Shape Shifting Cyclic Peptides (Sscp) And Their Use in The Identification of Novel Therapeutic Compounds | VIP, PTMS, QPCT | ADH1B 4788/4885ADH1C 4793/4885ADH1A 4774/4885 |
| US-20240199607-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 | ADH1B 228/4885ADH1C 638/4885ADH1A 983/4885 |
| US-20240199543-A1 | Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same | TOP2A, PAICS, TOP1 | ADH1B 1967/4885ADH1C 3129/4885ADH1A 3310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.